Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines
Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines
复制标题
DOI：
10.1158/2326-6066.cir-13-0022
复制
发表时间：
2013-07-01
影响因子：
10.1
通讯作者：
Wu, Catherine J.
中科院分区：
文献类型：
--
作者：
Hacohen, Nir;Fritsch, Edward F.;Wu, Catherine J.
尽管经过多年的临床前努力和数百项临床研究，具有限制或消除人类肿瘤生长的常规能力的治疗性癌症疫苗一直难以实现。随着基因组测序的进步，现在可以鉴定一类新的肿瘤特异性抗原，这些抗原源自仅存在于肿瘤中的突变蛋白。这些“新抗原”应该为抗肿瘤免疫提供高度特异性的靶标。尽管在生产和测试为每位患者定制的基于新抗原的疫苗方面仍然存在许多挑战，但新抗原疫苗提供了一种有前途的新方法来诱导高度集中的抗肿瘤 T 细胞，旨在根除癌细胞。 (C)2013 AACR。
Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer vaccines with the routine ability to limit or eliminate tumor growth in humans have been elusive. With advances in genome sequencing, it is now possible to identify a new class of tumor-specific antigens derived from mutated proteins that are present only in the tumor. These "neoantigens" should provide highly specific targets for antitumor immunity. Although many challenges remain in producing and testing neoantigen-based vaccines customized for each patient, a neoantigen vaccine offers a promising new approach to induce highly focused antitumor T cells aimed at eradicating cancer cells. (C)2013 AACR.